{"transactions":[{"id":4618660,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51309,"kind":"person","name":"Huizenga Theodore Alan","position":1,"cik":"0001603347","reported_name":"Huizenga Theodore Alan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-09-15T22:57:31.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":1283,"price":13.57,"value":17410.31,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":67863,"source":{"system":"sec-edgar","filing":"0001193125-26-392233","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1603347/000119312526392233/ownership.xml","form_type":"4"}},{"id":3414234,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51309,"kind":"person","name":"Huizenga Theodore Alan","position":1,"cik":"0001603347","reported_name":"Huizenga Theodore Alan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-09-08T16:29:52.000Z","date":"2026-09-03","kind":"sale","planned":false,"acquired":false,"shares":161,"price":13.99,"value":2252.39,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold to pay required tax withholdings due to the vesting of RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 396 shares acquired under the Company's Amended and Restated Employee Stock Purchase Place on April 30, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":69146,"source":{"system":"sec-edgar","filing":"0001193125-26-384878","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1603347/000119312526384878/ownership.xml","form_type":"4"}},{"id":696941,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":26580,"kind":"person","name":"Parschauer Karah Herdman","position":1,"cik":"0001677455","reported_name":"Parschauer Karah Herdman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-08-04T19:15:32.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":1900,"price":24.92,"value":47348.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":92562,"source":{"system":"sec-edgar","filing":"0001193125-26-332547","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526332547/ownership.xml","form_type":"4"}},{"id":696940,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":26579,"kind":"person","name":"Horn Howard","position":1,"cik":"0001786335","reported_name":"Horn Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-04T19:13:52.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":4696,"price":24.92,"value":117024.32,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":96295,"source":{"system":"sec-edgar","filing":"0001193125-26-332536","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526332536/ownership.xml","form_type":"4"}},{"id":714561,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":26579,"kind":"person","name":"Horn Howard","position":1,"cik":"0001786335","reported_name":"Horn Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-06T19:37:09.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":4698,"price":33.13,"value":155644.74,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":100991,"source":{"system":"sec-edgar","filing":"0001193125-26-296128","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526296128/ownership.xml","form_type":"4"}},{"id":737490,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":21675,"kind":"person","name":"Sanders Corazon (Corsee) D.","position":1,"cik":"0001796536","reported_name":"Sanders Corazon (Corsee) D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-15T22:50:54.000Z","date":"2026-06-15","kind":"sale","planned":false,"acquired":false,"shares":2000,"price":25.05,"value":50100.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":21095,"source":{"system":"sec-edgar","filing":"0001796536-26-000007","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000179653626000007/ownership.xml","form_type":"4"}},{"id":737489,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":26580,"kind":"person","name":"Parschauer Karah Herdman","position":1,"cik":"0001677455","reported_name":"Parschauer Karah Herdman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-06-15T22:46:33.000Z","date":"2026-06-15","kind":"sale","planned":true,"acquired":false,"shares":1899,"price":24.62,"value":46753.38,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 646 shares acquired under the Company's Amended and Restated Employee Stock Purchase Place on April 30, 2026"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":94462,"source":{"system":"sec-edgar","filing":"0001677455-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000167745526000002/ownership.xml","form_type":"4"}},{"id":756760,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":26579,"kind":"person","name":"Horn Howard","position":1,"cik":"0001786335","reported_name":"Horn Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-01T23:11:52.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":4653,"price":23.77,"value":110601.81,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":105689,"source":{"system":"sec-edgar","filing":"0001786335-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000178633526000002/ownership.xml","form_type":"4"}},{"id":774489,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-18T22:50:58.000Z","date":"2026-05-14","kind":"grant","planned":false,"acquired":true,"shares":14058,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027."}],"balance_after":14058,"derivative":{"exercise_price":25.8,"expiration_date":"2036-05-14","underlying":"Common Stock","underlying_shares":14058},"source":{"system":"sec-edgar","filing":"0001397266-26-000002","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1397266/000139726626000002/ownership.xml","form_type":"4"}},{"id":774488,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-18T22:50:58.000Z","date":"2026-05-14","kind":"grant","planned":false,"acquired":true,"shares":7751,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027."}],"balance_after":33696,"source":{"system":"sec-edgar","filing":"0001397266-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1397266/000139726626000002/ownership.xml","form_type":"4"}},{"id":774433,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":19373,"kind":"person","name":"SULIMAN SHEHNAAZ","position":1,"cik":"0001713070","reported_name":"SULIMAN SHEHNAAZ","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-18T22:41:18.000Z","date":"2026-05-14","kind":"grant","planned":true,"acquired":true,"shares":14058,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027."}],"balance_after":14058,"derivative":{"exercise_price":25.8,"expiration_date":"2036-05-14","underlying":"Common Stock","underlying_shares":14058},"source":{"system":"sec-edgar","filing":"0001713070-26-000002","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000171307026000002/ownership.xml","form_type":"4"}},{"id":774432,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":19373,"kind":"person","name":"SULIMAN SHEHNAAZ","position":1,"cik":"0001713070","reported_name":"SULIMAN SHEHNAAZ","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-18T22:41:18.000Z","date":"2026-05-18","kind":"sale","planned":true,"acquired":false,"shares":5740,"price":25.12,"value":144188.8,"ownership":{"direct":true},"balance_after":27951,"source":{"system":"sec-edgar","filing":"0001713070-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000171307026000002/ownership.xml","form_type":"4"}},{"id":774431,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":19373,"kind":"person","name":"SULIMAN SHEHNAAZ","position":1,"cik":"0001713070","reported_name":"SULIMAN SHEHNAAZ","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-18T22:41:18.000Z","date":"2026-05-14","kind":"grant","planned":true,"acquired":true,"shares":7751,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027."}],"balance_after":33691,"source":{"system":"sec-edgar","filing":"0001713070-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000171307026000002/ownership.xml","form_type":"4"}},{"id":774430,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":21675,"kind":"person","name":"Sanders Corazon (Corsee) D.","position":1,"cik":"0001796536","reported_name":"Sanders Corazon (Corsee) D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-18T22:38:30.000Z","date":"2026-05-14","kind":"grant","planned":false,"acquired":true,"shares":14058,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027."}],"balance_after":14058,"derivative":{"exercise_price":25.8,"expiration_date":"2036-05-14","underlying":"Common Stock","underlying_shares":14058},"source":{"system":"sec-edgar","filing":"0001796536-26-000004","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000179653626000004/ownership.xml","form_type":"4"}},{"id":774429,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":21675,"kind":"person","name":"Sanders Corazon (Corsee) D.","position":1,"cik":"0001796536","reported_name":"Sanders Corazon (Corsee) D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-18T22:38:30.000Z","date":"2026-05-14","kind":"grant","planned":false,"acquired":true,"shares":7751,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027."}],"balance_after":23095,"source":{"system":"sec-edgar","filing":"0001796536-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000179653626000004/ownership.xml","form_type":"4"}},{"id":774623,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":36750,"kind":"person","name":"WELCH DANIEL G","position":1,"cik":"0001206199","reported_name":"WELCH DANIEL G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-18T22:23:17.000Z","date":"2026-05-14","kind":"grant","planned":false,"acquired":true,"shares":14058,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027."}],"balance_after":14058,"derivative":{"exercise_price":25.8,"expiration_date":"2036-05-14","underlying":"Common Stock","underlying_shares":14058},"source":{"system":"sec-edgar","filing":"0001193125-26-229224","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1206199/000119312526229224/ownership.xml","form_type":"4"}},{"id":774622,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":36750,"kind":"person","name":"WELCH DANIEL G","position":1,"cik":"0001206199","reported_name":"WELCH DANIEL G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-18T22:23:17.000Z","date":"2026-05-14","kind":"grant","planned":false,"acquired":true,"shares":7751,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027."}],"balance_after":40441,"source":{"system":"sec-edgar","filing":"0001193125-26-229224","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1206199/000119312526229224/ownership.xml","form_type":"4"}},{"id":774529,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":29044,"kind":"person","name":"Dunsire Deborah","position":1,"cik":"0001332764","reported_name":"Dunsire Deborah","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-18T22:21:00.000Z","date":"2026-05-14","kind":"grant","planned":false,"acquired":true,"shares":14058,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027."}],"balance_after":14058,"derivative":{"exercise_price":25.8,"expiration_date":"2036-05-14","underlying":"Common Stock","underlying_shares":14058},"source":{"system":"sec-edgar","filing":"0001193125-26-229222","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1332764/000119312526229222/ownership.xml","form_type":"4"}},{"id":774528,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":29044,"kind":"person","name":"Dunsire Deborah","position":1,"cik":"0001332764","reported_name":"Dunsire Deborah","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-18T22:21:00.000Z","date":"2026-05-14","kind":"grant","planned":false,"acquired":true,"shares":7751,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027."}],"balance_after":38566,"source":{"system":"sec-edgar","filing":"0001193125-26-229222","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1332764/000119312526229222/ownership.xml","form_type":"4"}},{"id":775809,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":39030,"kind":"person","name":"Ray Amrit","position":1,"cik":"0001924797","reported_name":"Ray Amrit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-18T18:39:51.000Z","date":"2026-05-14","kind":"grant","planned":false,"acquired":true,"shares":14058,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027."}],"balance_after":14058,"derivative":{"exercise_price":25.8,"expiration_date":"2036-05-14","underlying":"Common Stock","underlying_shares":14058},"source":{"system":"sec-edgar","filing":"0001924797-26-000002","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1924797/000192479726000002/ownership.xml","form_type":"4"}},{"id":775808,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":39030,"kind":"person","name":"Ray Amrit","position":1,"cik":"0001924797","reported_name":"Ray Amrit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-18T18:39:51.000Z","date":"2026-05-14","kind":"grant","planned":false,"acquired":true,"shares":7751,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027."}],"balance_after":31116,"source":{"system":"sec-edgar","filing":"0001924797-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1924797/000192479726000002/ownership.xml","form_type":"4"}},{"id":774507,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":46351,"kind":"person","name":"NARACHI MICHAEL","position":1,"cik":"0001380022","reported_name":"NARACHI MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-18T18:35:50.000Z","date":"2026-05-14","kind":"grant","planned":false,"acquired":true,"shares":14058,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027."}],"balance_after":14058,"derivative":{"exercise_price":25.8,"expiration_date":"2036-05-14","underlying":"Common Stock","underlying_shares":14058},"source":{"system":"sec-edgar","filing":"0001380022-26-000002","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1380022/000138002226000002/ownership.xml","form_type":"4"}},{"id":774506,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":46351,"kind":"person","name":"NARACHI MICHAEL","position":1,"cik":"0001380022","reported_name":"NARACHI MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-18T18:35:50.000Z","date":"2026-05-14","kind":"grant","planned":false,"acquired":true,"shares":7751,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027."}],"balance_after":40441,"source":{"system":"sec-edgar","filing":"0001380022-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1380022/000138002226000002/ownership.xml","form_type":"4"}},{"id":789567,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":47139,"kind":"person","name":"Crombez Eric","position":1,"cik":"0001653052","reported_name":"Crombez Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-06T18:51:11.000Z","date":"2026-05-05","kind":"sale","planned":false,"acquired":false,"shares":344,"price":24.96,"value":8586.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold to pay required tax withholdings due to the vesting of RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 558 shares acquired under the Company's Amended and Restated Employee Stock Purchase Plan on April 30, 2026"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":111189,"source":{"system":"sec-edgar","filing":"0001193125-26-208632","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526208632/ownership.xml","form_type":"4"}},{"id":793565,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":26579,"kind":"person","name":"Horn Howard","position":1,"cik":"0001786335","reported_name":"Horn Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-04T21:35:58.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":4683,"price":24.9,"value":116606.7,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":110342,"source":{"system":"sec-edgar","filing":"0001193125-26-204402","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526204402/ownership.xml","form_type":"4"}},{"id":800770,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51309,"kind":"person","name":"Huizenga Theodore Alan","position":1,"cik":"0001603347","reported_name":"Huizenga Theodore Alan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-24T20:39:40.000Z","date":"2026-04-22","kind":"grant","planned":false,"acquired":true,"shares":7348,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On the first anniversary of the grant date of the option (the \"Option Anniversary Date\"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date."}],"balance_after":7348,"derivative":{"exercise_price":24.61,"expiration_date":"2036-04-22","underlying":"Common Stock","underlying_shares":7348},"source":{"system":"sec-edgar","filing":"0001193125-26-177470","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526177470/ownership.xml","form_type":"4"}},{"id":800769,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51309,"kind":"person","name":"Huizenga Theodore Alan","position":1,"cik":"0001603347","reported_name":"Huizenga Theodore Alan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-04-24T20:39:40.000Z","date":"2026-04-22","kind":"grant","planned":false,"acquired":true,"shares":20241,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":68911,"source":{"system":"sec-edgar","filing":"0001193125-26-177470","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526177470/ownership.xml","form_type":"4"}},{"id":804385,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-20T21:19:30.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":132693,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On the first anniversary of the grant date of the option (the \"Option Anniversary Date\"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date."}],"balance_after":132693,"derivative":{"exercise_price":24.52,"expiration_date":"2036-04-16","underlying":"Common Stock","underlying_shares":132693},"source":{"system":"sec-edgar","filing":"0001193125-26-164308","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000119312526164308/ownership.xml","form_type":"4"}},{"id":804384,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-04-20T21:19:30.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":76745,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":735739,"source":{"system":"sec-edgar","filing":"0001193125-26-164308","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000119312526164308/ownership.xml","form_type":"4"}},{"id":804339,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51928,"kind":"person","name":"Huang Dennis Karl","position":1,"cik":"0001641217","reported_name":"Huang Dennis Karl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-20T21:17:52.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":79936,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On the first anniversary of the grant date of the option (the \"Option Anniversary Date\"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date."}],"balance_after":79936,"derivative":{"exercise_price":24.52,"expiration_date":"2036-04-16","underlying":"Common Stock","underlying_shares":79936},"source":{"system":"sec-edgar","filing":"0001193125-26-164297","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526164297/ownership.xml","form_type":"4"}},{"id":804338,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51928,"kind":"person","name":"Huang Dennis Karl","position":1,"cik":"0001641217","reported_name":"Huang Dennis Karl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-04-20T21:17:52.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":23116,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":147845,"source":{"system":"sec-edgar","filing":"0001193125-26-164297","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526164297/ownership.xml","form_type":"4"}},{"id":804335,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51927,"kind":"person","name":"Pinion John Richard","position":1,"cik":"0001648096","reported_name":"Pinion John Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-20T21:16:25.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":79936,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On the first anniversary of the grant date of the option (the \"Option Anniversary Date\"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date."}],"balance_after":79936,"derivative":{"exercise_price":24.52,"expiration_date":"2036-04-16","underlying":"Common Stock","underlying_shares":79936},"source":{"system":"sec-edgar","filing":"0001193125-26-164289","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526164289/ownership.xml","form_type":"4"}},{"id":804334,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51927,"kind":"person","name":"Pinion John Richard","position":1,"cik":"0001648096","reported_name":"Pinion John Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-04-20T21:16:25.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":23116,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":133142,"source":{"system":"sec-edgar","filing":"0001193125-26-164289","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526164289/ownership.xml","form_type":"4"}},{"id":804337,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":26580,"kind":"person","name":"Parschauer Karah Herdman","position":1,"cik":"0001677455","reported_name":"Parschauer Karah Herdman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-20T21:15:00.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":49960,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On the first anniversary of the grant date of the option (the \"Option Anniversary Date\"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date."}],"balance_after":49960,"derivative":{"exercise_price":24.52,"expiration_date":"2036-04-16","underlying":"Common Stock","underlying_shares":49960},"source":{"system":"sec-edgar","filing":"0001193125-26-164281","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526164281/ownership.xml","form_type":"4"}},{"id":804336,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":26580,"kind":"person","name":"Parschauer Karah Herdman","position":1,"cik":"0001677455","reported_name":"Parschauer Karah Herdman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-04-20T21:15:00.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":28895,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":95715,"source":{"system":"sec-edgar","filing":"0001193125-26-164281","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526164281/ownership.xml","form_type":"4"}},{"id":804333,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-20T21:13:09.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":49960,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On the first anniversary of the grant date of the option (the \"Option Anniversary Date\"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date."}],"balance_after":49960,"derivative":{"exercise_price":24.52,"expiration_date":"2036-04-16","underlying":"Common Stock","underlying_shares":49960},"source":{"system":"sec-edgar","filing":"0001193125-26-164267","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526164267/ownership.xml","form_type":"4"}},{"id":804332,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-04-20T21:13:09.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":28895,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":118410,"source":{"system":"sec-edgar","filing":"0001193125-26-164267","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526164267/ownership.xml","form_type":"4"}},{"id":804329,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":47139,"kind":"person","name":"Crombez Eric","position":1,"cik":"0001653052","reported_name":"Crombez Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-20T21:11:06.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":59952,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On the first anniversary of the grant date of the option (the \"Option Anniversary Date\"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date."}],"balance_after":59952,"derivative":{"exercise_price":24.52,"expiration_date":"2036-04-16","underlying":"Common Stock","underlying_shares":59952},"source":{"system":"sec-edgar","filing":"0001193125-26-164257","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526164257/ownership.xml","form_type":"4"}},{"id":804328,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":47139,"kind":"person","name":"Crombez Eric","position":1,"cik":"0001653052","reported_name":"Crombez Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-04-20T21:11:06.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":34674,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":110975,"source":{"system":"sec-edgar","filing":"0001193125-26-164257","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526164257/ownership.xml","form_type":"4"}},{"id":804331,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":26579,"kind":"person","name":"Horn Howard","position":1,"cik":"0001786335","reported_name":"Horn Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-20T21:09:33.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":59952,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On the first anniversary of the grant date of the option (the \"Option Anniversary Date\"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date."}],"balance_after":59952,"derivative":{"exercise_price":24.52,"expiration_date":"2036-04-16","underlying":"Common Stock","underlying_shares":59952},"source":{"system":"sec-edgar","filing":"0001193125-26-164247","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526164247/ownership.xml","form_type":"4"}},{"id":804330,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":26579,"kind":"person","name":"Horn Howard","position":1,"cik":"0001786335","reported_name":"Horn Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-04-20T21:09:33.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":34674,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":115025,"source":{"system":"sec-edgar","filing":"0001193125-26-164247","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526164247/ownership.xml","form_type":"4"}},{"id":819043,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":26579,"kind":"person","name":"Horn Howard","position":1,"cik":"0001786335","reported_name":"Horn Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-04-02T22:19:58.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":4683,"price":20.97,"value":98202.51,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":80351,"source":{"system":"sec-edgar","filing":"0001193125-26-140702","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526140702/ownership.xml","form_type":"4"}},{"id":850442,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":26580,"kind":"person","name":"Parschauer Karah Herdman","position":1,"cik":"0001677455","reported_name":"Parschauer Karah Herdman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-03-10T20:51:40.000Z","date":"2026-03-10","kind":"sale","planned":false,"acquired":false,"shares":3508,"price":22.67,"value":79526.36,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":66820,"source":{"system":"sec-edgar","filing":"0001193125-26-100309","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526100309/ownership.xml","form_type":"4"}},{"id":850441,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":26580,"kind":"person","name":"Parschauer Karah Herdman","position":1,"cik":"0001677455","reported_name":"Parschauer Karah Herdman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-03-10T20:51:40.000Z","date":"2026-03-06","kind":"sale","planned":false,"acquired":false,"shares":6018,"price":21.4,"value":128785.2,"ownership":{"direct":true},"balance_after":70328,"source":{"system":"sec-edgar","filing":"0001193125-26-100309","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526100309/ownership.xml","form_type":"4"}},{"id":865578,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51927,"kind":"person","name":"Pinion John Richard","position":1,"cik":"0001648096","reported_name":"Pinion John Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-03-04T00:09:43.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":10029,"price":22.8,"value":228661.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to pay required tax withholdings due to the vesting of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.54 to $23.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 490 shares acquired under the Company's Amended and Restated Employee Stock Purchase Plan on April 30, 2025"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":110026,"source":{"system":"sec-edgar","filing":"0001193125-26-089287","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526089287/ownership.xml","form_type":"4"}},{"id":865577,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51927,"kind":"person","name":"Pinion John Richard","position":1,"cik":"0001648096","reported_name":"Pinion John Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-03-04T00:09:43.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":11137,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock which previously granted performance stock units were converted on March 1, 2026 upon certification of the performance metrics."}],"balance_after":119565,"source":{"system":"sec-edgar","filing":"0001193125-26-089287","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526089287/ownership.xml","form_type":"4"}},{"id":865580,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-03-04T00:08:17.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":10539,"price":22.8,"value":240289.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to pay required tax withholdings due to the vesting of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.54 to $23.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes a total of 556 shares acquired under the Company's Amended and Restated Employee Stock Purchase Plan on April 30, 2025 and October 31, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":89515,"source":{"system":"sec-edgar","filing":"0001193125-26-089282","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526089282/ownership.xml","form_type":"4"}},{"id":865579,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-03-04T00:08:17.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":11643,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock which previously granted performance stock units were converted on March 1, 2026 upon certification of the performance metrics."}],"balance_after":99498,"source":{"system":"sec-edgar","filing":"0001193125-26-089282","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526089282/ownership.xml","form_type":"4"}},{"id":866020,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-03-04T00:06:19.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":54404,"price":22.8,"value":1240411.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to pay required tax withholdings due to the vesting of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.54 to $23.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 490 shares acquired under the Company's Amended and Restated Employee Stock Purchase Plan on April 30, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":658994,"source":{"system":"sec-edgar","filing":"0001193125-26-089278","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000119312526089278/ownership.xml","form_type":"4"}},{"id":866019,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51931,"kind":"person","name":"KAKKIS EMIL D","position":1,"cik":"0001248093","reported_name":"KAKKIS EMIL D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-03-04T00:06:19.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":71177,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock which previously granted performance stock units were converted on March 1, 2026 upon certification of the performance metrics."}],"balance_after":712908,"source":{"system":"sec-edgar","filing":"0001193125-26-089278","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248093/000119312526089278/ownership.xml","form_type":"4"}},{"id":865576,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":26580,"kind":"person","name":"Parschauer Karah Herdman","position":1,"cik":"0001677455","reported_name":"Parschauer Karah Herdman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-03-03T23:51:48.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":8135,"price":22.8,"value":185478.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to pay required tax withholdings due to the vesting of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.54 to $23.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 73 shares acquired under the Company's Amended and Restated Employee Stock Purchase Plan on October 31, 2025"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":76346,"source":{"system":"sec-edgar","filing":"0001193125-26-089111","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526089111/ownership.xml","form_type":"4"}},{"id":865575,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":26580,"kind":"person","name":"Parschauer Karah Herdman","position":1,"cik":"0001677455","reported_name":"Parschauer Karah Herdman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-03-03T23:51:48.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":11137,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock which previously granted performance stock units were converted on March 1, 2026 upon certification of the performance metrics."}],"balance_after":84408,"source":{"system":"sec-edgar","filing":"0001193125-26-089111","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526089111/ownership.xml","form_type":"4"}},{"id":865574,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51309,"kind":"person","name":"Huizenga Theodore Alan","position":1,"cik":"0001603347","reported_name":"Huizenga Theodore Alan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-03-03T23:51:08.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":1632,"price":22.8,"value":37209.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to pay required tax withholdings due to the vesting of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.54 to $23.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":48670,"source":{"system":"sec-edgar","filing":"0001193125-26-089109","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526089109/ownership.xml","form_type":"4"}},{"id":865573,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51309,"kind":"person","name":"Huizenga Theodore Alan","position":1,"cik":"0001603347","reported_name":"Huizenga Theodore Alan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-03-03T23:51:08.000Z","date":"2026-03-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":148,"price":23.39,"value":3461.72,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs."}],"balance_after":50302,"source":{"system":"sec-edgar","filing":"0001193125-26-089109","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526089109/ownership.xml","form_type":"4"}},{"id":865572,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":26579,"kind":"person","name":"Horn Howard","position":1,"cik":"0001786335","reported_name":"Horn Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-03T23:50:25.000Z","date":"2026-03-03","kind":"sale","planned":true,"acquired":false,"shares":1635,"price":22.4,"value":36624.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":85034,"source":{"system":"sec-edgar","filing":"0001193125-26-089107","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526089107/ownership.xml","form_type":"4"}},{"id":865571,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":26579,"kind":"person","name":"Horn Howard","position":1,"cik":"0001786335","reported_name":"Horn Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-03T23:50:25.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":3119,"price":22.54,"value":70302.26,"ownership":{"direct":true},"balance_after":86669,"source":{"system":"sec-edgar","filing":"0001193125-26-089107","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526089107/ownership.xml","form_type":"4"}},{"id":865570,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":26579,"kind":"person","name":"Horn Howard","position":1,"cik":"0001786335","reported_name":"Horn Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-03T23:50:25.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":5290,"price":22.8,"value":120612.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to pay required tax withholdings due to the vesting of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.54 to $23.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range"}],"balance_after":89788,"source":{"system":"sec-edgar","filing":"0001193125-26-089107","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526089107/ownership.xml","form_type":"4"}},{"id":865569,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":26579,"kind":"person","name":"Horn Howard","position":1,"cik":"0001786335","reported_name":"Horn Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-03T23:50:25.000Z","date":"2026-03-01","kind":"grant","planned":true,"acquired":true,"shares":6143,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock which previously granted performance stock units were converted on March 1, 2026 upon certification of the performance metric."}],"balance_after":95078,"source":{"system":"sec-edgar","filing":"0001193125-26-089107","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526089107/ownership.xml","form_type":"4"}},{"id":865568,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":47139,"kind":"person","name":"Crombez Eric","position":1,"cik":"0001653052","reported_name":"Crombez Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-03-03T23:49:45.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":7029,"price":22.8,"value":160261.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to pay required tax withholdings due to the vesting of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.54 to $23.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 157 shares acquired on October 30, 2025 under the Company's Amended and Restated Employee Stock Purchase Plan"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":76301,"source":{"system":"sec-edgar","filing":"0001193125-26-089104","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526089104/ownership.xml","form_type":"4"}},{"id":865567,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":47139,"kind":"person","name":"Crombez Eric","position":1,"cik":"0001653052","reported_name":"Crombez Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-03-03T23:49:45.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":11643,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock which previously granted performance stock units were converted on March 1, 2026 upon certification of the performance metrics."}],"balance_after":83173,"source":{"system":"sec-edgar","filing":"0001193125-26-089104","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526089104/ownership.xml","form_type":"4"}},{"id":865566,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51928,"kind":"person","name":"Huang Dennis Karl","position":1,"cik":"0001641217","reported_name":"Huang Dennis Karl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-03-03T23:49:10.000Z","date":"2026-03-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":999,"price":23.39,"value":23366.61,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":124729,"source":{"system":"sec-edgar","filing":"0001193125-26-089102","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526089102/ownership.xml","form_type":"4"}},{"id":865565,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51928,"kind":"person","name":"Huang Dennis Karl","position":1,"cik":"0001641217","reported_name":"Huang Dennis Karl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-03-03T23:49:10.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":11137,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock which previously granted performance stock units were converted on March 1, 2026 upon certification of the performance metric."}],"balance_after":125728,"source":{"system":"sec-edgar","filing":"0001193125-26-089102","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526089102/ownership.xml","form_type":"4"}},{"id":921248,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":26579,"kind":"person","name":"Horn Howard","position":1,"cik":"0001786335","reported_name":"Horn Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-03T17:00:41.000Z","date":"2026-02-02","kind":"sale","planned":true,"acquired":false,"shares":3061,"price":23.56,"value":72117.16,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":88935,"source":{"system":"sec-edgar","filing":"0001193125-26-034832","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526034832/ownership.xml","form_type":"4"}},{"id":950362,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":26579,"kind":"person","name":"Horn Howard","position":1,"cik":"0001786335","reported_name":"Horn Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:07:21.000Z","date":"2026-01-02","kind":"sale","planned":true,"acquired":false,"shares":3150,"price":22.84,"value":71946.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":91996,"source":{"system":"sec-edgar","filing":"0001193125-26-002410","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526002410/ownership.xml","form_type":"4"}},{"id":957018,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51309,"kind":"person","name":"Huizenga Theodore Alan","position":1,"cik":"0001603347","reported_name":"Huizenga Theodore Alan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-12-30T18:49:27.000Z","date":"2025-12-29","kind":"sale","planned":false,"acquired":false,"shares":85,"price":34.38,"value":2922.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares sold to pay required tax withholdings due to the vesting of RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 293 shares acquired under the Company's A&R 2014 Employee Stock Purchase Plan on October 31, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":50450,"source":{"system":"sec-edgar","filing":"0001193125-25-336619","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312525336619/ownership.xml","form_type":"4"}},{"id":972422,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":26579,"kind":"person","name":"Horn Howard","position":1,"cik":"0001786335","reported_name":"Horn Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-12-11T17:10:22.000Z","date":"2025-12-10","kind":"sale","planned":true,"acquired":false,"shares":3081,"price":36.38,"value":112086.78,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":95146,"source":{"system":"sec-edgar","filing":"0001193125-25-315460","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312525315460/ownership.xml","form_type":"4"}},{"id":1019036,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":26579,"kind":"person","name":"Horn Howard","position":1,"cik":"0001786335","reported_name":"Horn Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-10-14T16:15:06.000Z","date":"2025-10-13","kind":"sale","planned":false,"acquired":false,"shares":7942,"price":31.51,"value":250252.42,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold to pay required tax withholdings due to the vesting of RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":98227,"source":{"system":"sec-edgar","filing":"0001193125-25-238708","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312525238708/ownership.xml","form_type":"4"}},{"id":1035432,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51309,"kind":"person","name":"Huizenga Theodore Alan","position":1,"cik":"0001603347","reported_name":"Huizenga Theodore Alan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-09-19T22:23:43.000Z","date":"2025-09-18","kind":"sale","planned":false,"acquired":false,"shares":64,"price":29.17,"value":1866.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares sold to pay required tax withholdings due to the vesting of RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":50242,"source":{"system":"sec-edgar","filing":"0001193125-25-209387","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312525209387/ownership.xml","form_type":"4"}},{"id":1041291,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":26580,"kind":"person","name":"Parschauer Karah Herdman","position":1,"cik":"0001677455","reported_name":"Parschauer Karah Herdman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-09-12T20:11:58.000Z","date":"2025-09-12","kind":"sale","planned":false,"acquired":false,"shares":2450,"price":31.17,"value":76366.5,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 434 shares acquired under the Company's A&R 2014 Employee Stock Purchase Plan on April 30, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":73271,"source":{"system":"sec-edgar","filing":"0001677455-25-000005","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000167745525000005/ownership.xml","form_type":"4"}},{"id":1045623,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51309,"kind":"person","name":"Huizenga Theodore Alan","position":1,"cik":"0001603347","reported_name":"Huizenga Theodore Alan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-09-08T18:01:44.000Z","date":"2025-09-05","kind":"sale","planned":false,"acquired":false,"shares":84,"price":31.39,"value":2636.76,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold to pay required tax withholdings due to the vesting of RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 266 shares acquired under the Company's A&R 2014 Employee Stock Purchase Plan on April 30, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":50306,"source":{"system":"sec-edgar","filing":"0000950170-25-113446","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017025113446/ownership.xml","form_type":"4"}},{"id":1103513,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":21675,"kind":"person","name":"Sanders Corazon (Corsee) D.","position":1,"cik":"0001796536","reported_name":"Sanders Corazon (Corsee) D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-23T17:50:13.000Z","date":"2025-06-20","kind":"sale","planned":true,"acquired":false,"shares":2405,"price":37.39,"value":89922.95,"ownership":{"direct":true},"balance_after":15344,"source":{"system":"sec-edgar","filing":"0000950170-25-088878","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017025088878/ownership.xml","form_type":"4"}},{"id":1142067,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":19373,"kind":"person","name":"SULIMAN SHEHNAAZ","position":1,"cik":"0001713070","reported_name":"SULIMAN SHEHNAAZ","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-19T22:34:32.000Z","date":"2025-05-15","kind":"grant","planned":false,"acquired":true,"shares":10787,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 15, 2026."}],"balance_after":10787,"derivative":{"exercise_price":34.84,"expiration_date":"2035-05-15","underlying":"Common Stock","underlying_shares":10787},"source":{"system":"sec-edgar","filing":"0000950170-25-074669","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017025074669/ownership.xml","form_type":"4"}},{"id":1142066,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":19373,"kind":"person","name":"SULIMAN SHEHNAAZ","position":1,"cik":"0001713070","reported_name":"SULIMAN SHEHNAAZ","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-19T22:34:32.000Z","date":"2025-05-15","kind":"grant","planned":false,"acquired":true,"shares":5740,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 15, 2026."}],"balance_after":25940,"source":{"system":"sec-edgar","filing":"0000950170-25-074669","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017025074669/ownership.xml","form_type":"4"}},{"id":1142298,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":36750,"kind":"person","name":"WELCH DANIEL G","position":1,"cik":"0001206199","reported_name":"WELCH DANIEL G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-19T22:33:56.000Z","date":"2025-05-15","kind":"grant","planned":false,"acquired":true,"shares":10787,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 15, 2026."}],"balance_after":10787,"derivative":{"exercise_price":34.84,"expiration_date":"2035-05-15","underlying":"Common Stock","underlying_shares":10787},"source":{"system":"sec-edgar","filing":"0000950170-25-074667","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1206199/000095017025074667/ownership.xml","form_type":"4"}},{"id":1142297,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":36750,"kind":"person","name":"WELCH DANIEL G","position":1,"cik":"0001206199","reported_name":"WELCH DANIEL G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-19T22:33:56.000Z","date":"2025-05-15","kind":"grant","planned":false,"acquired":true,"shares":5740,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 15, 2026."}],"balance_after":32690,"source":{"system":"sec-edgar","filing":"0000950170-25-074667","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1206199/000095017025074667/ownership.xml","form_type":"4"}},{"id":1142065,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":21675,"kind":"person","name":"Sanders Corazon (Corsee) D.","position":1,"cik":"0001796536","reported_name":"Sanders Corazon (Corsee) D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-19T22:33:25.000Z","date":"2025-05-15","kind":"grant","planned":false,"acquired":true,"shares":10787,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 15, 2026."}],"balance_after":10787,"derivative":{"exercise_price":34.84,"expiration_date":"2035-05-15","underlying":"Common Stock","underlying_shares":10787},"source":{"system":"sec-edgar","filing":"0000950170-25-074666","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017025074666/ownership.xml","form_type":"4"}},{"id":1142064,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":21675,"kind":"person","name":"Sanders Corazon (Corsee) D.","position":1,"cik":"0001796536","reported_name":"Sanders Corazon (Corsee) D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-19T22:33:25.000Z","date":"2025-05-15","kind":"grant","planned":false,"acquired":true,"shares":5740,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 15, 2026."}],"balance_after":17749,"source":{"system":"sec-edgar","filing":"0000950170-25-074666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017025074666/ownership.xml","form_type":"4"}},{"id":1142080,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-19T22:32:13.000Z","date":"2025-05-15","kind":"grant","planned":false,"acquired":true,"shares":10787,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 15, 2026."}],"balance_after":10787,"derivative":{"exercise_price":34.84,"expiration_date":"2035-05-15","underlying":"Common Stock","underlying_shares":10787},"source":{"system":"sec-edgar","filing":"0000950170-25-074664","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1397266/000095017025074664/ownership.xml","form_type":"4"}},{"id":1142079,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-19T22:32:13.000Z","date":"2025-05-15","kind":"grant","planned":false,"acquired":true,"shares":5740,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 15, 2026."}],"balance_after":25945,"source":{"system":"sec-edgar","filing":"0000950170-25-074664","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1397266/000095017025074664/ownership.xml","form_type":"4"}},{"id":1142147,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":29044,"kind":"person","name":"Dunsire Deborah","position":1,"cik":"0001332764","reported_name":"Dunsire Deborah","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-19T22:31:42.000Z","date":"2025-05-15","kind":"grant","planned":false,"acquired":true,"shares":10787,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 15, 2026."}],"balance_after":10787,"derivative":{"exercise_price":34.84,"expiration_date":"2035-05-15","underlying":"Common Stock","underlying_shares":10787},"source":{"system":"sec-edgar","filing":"0000950170-25-074662","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1332764/000095017025074662/ownership.xml","form_type":"4"}},{"id":1142146,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":29044,"kind":"person","name":"Dunsire Deborah","position":1,"cik":"0001332764","reported_name":"Dunsire Deborah","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-19T22:31:42.000Z","date":"2025-05-15","kind":"grant","planned":false,"acquired":true,"shares":5740,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 15, 2026."}],"balance_after":30815,"source":{"system":"sec-edgar","filing":"0000950170-25-074662","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1332764/000095017025074662/ownership.xml","form_type":"4"}},{"id":1142124,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":46351,"kind":"person","name":"NARACHI MICHAEL","position":1,"cik":"0001380022","reported_name":"NARACHI MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-19T18:32:48.000Z","date":"2025-05-15","kind":"grant","planned":false,"acquired":true,"shares":10787,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 15, 2026."}],"balance_after":10787,"derivative":{"exercise_price":34.84,"expiration_date":"2035-05-15","underlying":"Common Stock","underlying_shares":10787},"source":{"system":"sec-edgar","filing":"0000950170-25-074665","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1380022/000095017025074665/ownership.xml","form_type":"4"}},{"id":1142123,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":46351,"kind":"person","name":"NARACHI MICHAEL","position":1,"cik":"0001380022","reported_name":"NARACHI MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-19T18:32:48.000Z","date":"2025-05-15","kind":"grant","planned":false,"acquired":true,"shares":5740,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 15, 2026."}],"balance_after":32690,"source":{"system":"sec-edgar","filing":"0000950170-25-074665","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1380022/000095017025074665/ownership.xml","form_type":"4"}},{"id":1143769,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":39030,"kind":"person","name":"Ray Amrit","position":1,"cik":"0001924797","reported_name":"Ray Amrit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-19T18:31:03.000Z","date":"2025-05-15","kind":"grant","planned":false,"acquired":true,"shares":10787,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 15, 2026."}],"balance_after":10787,"derivative":{"exercise_price":34.84,"expiration_date":"2035-05-15","underlying":"Common Stock","underlying_shares":10787},"source":{"system":"sec-edgar","filing":"0000950170-25-074661","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1924797/000095017025074661/ownership.xml","form_type":"4"}},{"id":1143768,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":39030,"kind":"person","name":"Ray Amrit","position":1,"cik":"0001924797","reported_name":"Ray Amrit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-19T18:31:03.000Z","date":"2025-05-15","kind":"grant","planned":false,"acquired":true,"shares":5740,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 15, 2026."}],"balance_after":23365,"source":{"system":"sec-edgar","filing":"0000950170-25-074661","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1924797/000095017025074661/ownership.xml","form_type":"4"}},{"id":1158758,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":47139,"kind":"person","name":"Crombez Eric","position":1,"cik":"0001653052","reported_name":"Crombez Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-05-05T23:18:48.000Z","date":"2025-05-05","kind":"sale","planned":false,"acquired":false,"shares":520,"price":39.24,"value":20404.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold to pay required tax withholdings due to the vesting of RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 370 shares acquired on April 30, 2025 under the Company's Amended and Restated Employee Stock Purchase Plan"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":71530,"source":{"system":"sec-edgar","filing":"0000950170-25-063792","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017025063792/ownership.xml","form_type":"4"}},{"id":1158757,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":47139,"kind":"person","name":"Crombez Eric","position":1,"cik":"0001653052","reported_name":"Crombez Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-05-05T23:18:48.000Z","date":"2025-04-21","kind":"sale","planned":false,"acquired":false,"shares":242,"price":35.11,"value":8496.62,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold to pay required tax withholdings due to the vesting of RSUs."}],"balance_after":71680,"source":{"system":"sec-edgar","filing":"0000950170-25-063792","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017025063792/ownership.xml","form_type":"4"}},{"id":1214632,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":26579,"kind":"person","name":"Horn Howard","position":1,"cik":"0001786335","reported_name":"Horn Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-10T16:53:00.000Z","date":"2025-03-06","kind":"sale","planned":false,"acquired":false,"shares":1785,"price":40.4,"value":72114.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold to pay required tax withholdings due to the vesting of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.73 to $41.37 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":106169,"source":{"system":"sec-edgar","filing":"0000950170-25-036056","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017025036056/ownership.xml","form_type":"4"}},{"id":1227575,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":45188,"kind":"person","name":"Kassberg Thomas Richard","position":1,"cik":"0001303811","reported_name":"Kassberg Thomas Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CBO & EVP"}}],"security":"Common Stock","published_at":"2025-03-05T01:19:57.000Z","date":"2025-03-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":508,"price":42.92,"value":21803.36,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":264730,"source":{"system":"sec-edgar","filing":"0000950170-25-032802","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1303811/000095017025032802/ownership.xml","form_type":"4"}},{"id":1227574,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":45188,"kind":"person","name":"Kassberg Thomas Richard","position":1,"cik":"0001303811","reported_name":"Kassberg Thomas Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CBO & EVP"}}],"security":"Common Stock","published_at":"2025-03-05T01:19:57.000Z","date":"2025-03-03","kind":"sale","planned":false,"acquired":false,"shares":6028,"price":42.1,"value":253778.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to pay required tax withholdings due to the vesting of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.77 to $42.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":265238,"source":{"system":"sec-edgar","filing":"0000950170-25-032802","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1303811/000095017025032802/ownership.xml","form_type":"4"}},{"id":1227573,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":45188,"kind":"person","name":"Kassberg Thomas Richard","position":1,"cik":"0001303811","reported_name":"Kassberg Thomas Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CBO & EVP"}}],"security":"Common Stock","published_at":"2025-03-05T01:19:57.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":18443,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock which previously granted performance stock units were converted on March 1, 2025 upon certification of the performance metric."}],"balance_after":271266,"source":{"system":"sec-edgar","filing":"0000950170-25-032802","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1303811/000095017025032802/ownership.xml","form_type":"4"}},{"id":1226918,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":26580,"kind":"person","name":"Parschauer Karah Herdman","position":1,"cik":"0001677455","reported_name":"Parschauer Karah Herdman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-03-05T01:18:24.000Z","date":"2025-03-03","kind":"sale","planned":false,"acquired":false,"shares":12846,"price":42.1,"value":540816.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to pay required tax withholdings due to the vesting of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.77 to $42.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":75287,"source":{"system":"sec-edgar","filing":"0000950170-25-032798","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017025032798/ownership.xml","form_type":"4"}},{"id":1226917,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":26580,"kind":"person","name":"Parschauer Karah Herdman","position":1,"cik":"0001677455","reported_name":"Parschauer Karah Herdman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-03-05T01:18:24.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":18443,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock which previously granted performance stock units were converted on March 1, 2025 upon certification of the performance metric."}],"balance_after":88133,"source":{"system":"sec-edgar","filing":"0000950170-25-032798","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017025032798/ownership.xml","form_type":"4"}},{"id":1226916,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":47139,"kind":"person","name":"Crombez Eric","position":1,"cik":"0001653052","reported_name":"Crombez Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Stock Ooption (Right to Buy)","published_at":"2025-03-05T01:16:48.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":30246,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"On the first anniversary of the grant date of the option (the \"Option Anniversary Date\"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date."}],"balance_after":30246,"derivative":{"exercise_price":42.92,"expiration_date":"2035-03-01","underlying":"Common Stock","underlying_shares":30246},"source":{"system":"sec-edgar","filing":"0000950170-25-032794","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017025032794/ownership.xml","form_type":"4"}},{"id":1226915,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":47139,"kind":"person","name":"Crombez Eric","position":1,"cik":"0001653052","reported_name":"Crombez Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-03-05T01:16:48.000Z","date":"2025-03-03","kind":"sale","planned":false,"acquired":false,"shares":8945,"price":42.1,"value":376584.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares sold to pay required tax withholdings due to the vesting of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.77 to $42.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Includes 652 shares acquired on April 30, 2024 and October 31, 2024 under the Company's Amended and Restated Employee Stock Purchase Plan"}],"balance_after":71922,"source":{"system":"sec-edgar","filing":"0000950170-25-032794","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017025032794/ownership.xml","form_type":"4"}},{"id":1226914,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":47139,"kind":"person","name":"Crombez Eric","position":1,"cik":"0001653052","reported_name":"Crombez Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-03-05T01:16:48.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":14971,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of common stock which previously granted performance stock units were converted on March 1, 2025 upon certification of the performance metric."}],"balance_after":80215,"source":{"system":"sec-edgar","filing":"0000950170-25-032794","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017025032794/ownership.xml","form_type":"4"}},{"id":1226913,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":47139,"kind":"person","name":"Crombez Eric","position":1,"cik":"0001653052","reported_name":"Crombez Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-03-05T01:16:48.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":16813,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date"}],"balance_after":65244,"source":{"system":"sec-edgar","filing":"0000950170-25-032794","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017025032794/ownership.xml","form_type":"4"}},{"id":1226912,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51927,"kind":"person","name":"Pinion John Richard","position":1,"cik":"0001648096","reported_name":"Pinion John Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-05T01:12:26.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":26074,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"On the first anniversary of the grant date of the option (the \"Option Anniversary Date\"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date."}],"balance_after":26074,"derivative":{"exercise_price":42.92,"expiration_date":"2035-03-01","underlying":"Commmon Stock","underlying_shares":26074},"source":{"system":"sec-edgar","filing":"0000950170-25-032785","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017025032785/ownership.xml","form_type":"4"}},{"id":1226911,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51927,"kind":"person","name":"Pinion John Richard","position":1,"cik":"0001648096","reported_name":"Pinion John Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-03-05T01:12:26.000Z","date":"2025-03-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":31,"price":42.92,"value":1330.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"Includes 693 shares acquired under the Company's Amended & Restated Employee Stock Purchase Plan on April 30, 2024"}],"balance_after":108428,"source":{"system":"sec-edgar","filing":"0000950170-25-032785","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017025032785/ownership.xml","form_type":"4"}},{"id":1226910,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51927,"kind":"person","name":"Pinion John Richard","position":1,"cik":"0001648096","reported_name":"Pinion John Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-03-05T01:12:26.000Z","date":"2025-03-03","kind":"sale","planned":false,"acquired":false,"shares":14439,"price":42.1,"value":607881.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares sold to pay required tax withholdings due to the vesting of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.77 to $42.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":107766,"source":{"system":"sec-edgar","filing":"0000950170-25-032785","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017025032785/ownership.xml","form_type":"4"}}],"next_cursor":"2025-03-05T01:12:26.000000Z,1226910"}